WHAT IS CLAIMED IS:

1. Use of a therapeutically effective amount of a caspase inhibitor in the manufacture of a medicament for treating a liver disease in a subject, wherein the subject has a MELD score of at least 10.

2. The use of claim 1, wherein the MELD score is reduced by at least 1 point.

3. The use of claim 1, wherein the subject has an elevated MELD score or elevated components of MELD; and the caspase inhibitor is to be administered to the subject.

4. The use of claim 3, wherein the MELD score is above 10.

5. The use of any one of claims 1-4, wherein the MELD score is above 14.

6. The use of any one of claims 1-5, wherein the MELD score is sustained.

7. The use of any one of claims 1-6, wherein the MELD score is reduced.

8. The use of any one of claims 1-7, wherein the MELD score is reduced by at least 1 point.

9. The use of any one of claims 1-8, wherein the MELD score is reduced by at least 2 points.

10. The use of any one of claims 1-9, wherein the MELD score is reduced below 15.

11. Use of a therapeutically effective amount of a caspase inhibitor in the manufacture of a medicament for treating a liver disease in a subject, wherein the subject has an elevated Child-Pugh score or its components, the caspase inhibitor is to be administered to the subject.

12. The use of any one of claims 1-11, wherein the liver disease is cirrhosis.

13. The use of any one of claims 11-12, wherein the Child-Pugh score is above Class A.

14. The use of any one of claims 11-13, wherein the Child-Pugh score is above Class B.

15. The use of any one of claims 11-14, wherein the Child-Pugh score is sustained.

16. The use of any one of claims 11-14, wherein the Child-Pugh score is reduced.


17. The use of any one of claims 11-14, wherein the Child-Pugh score is reduced by at least 1 point.

18. The use of any one of claims 11-14, wherein the Child-Pugh score is reduced by at least 2 points.


19. The use of any one of claims 11-14, wherein the Child-Pugh score is reduced below Class B.

20. The use of any one of claims 11-14, wherein the Child-Pugh score is reduced below Class C.


21. The use of any one of claims 1-20, wherein the caspase inhibitor is selected from:




IDN6556, emricasan




IDN7314




IDN6734




CTS5814




IDN7568




CTS2891




IDN8126



IDN9103




VX-166




VX-765, belnacasan

or a pharmaceutically acceptable derivative thereof.


22. The use according to any one of claims 1-20, wherein the caspase inhibitor is selected from:




IDN6556, emricasan




IDN7314




IDN6734



CTS5814




IDN7568




CTS2891

or a pharmaceutically acceptable derivative thereof.

23. The use according to any one of claims 1-20, wherein the caspase inhibitor is selected from:




IDN6556, emricasan



VX-166

or a pharmaceutically acceptable derivative thereof.


24. The method according to claim 24, wherein the caspase inhibitor is:



IDN6556, emricasan

or a pharmaceutically acceptable derivative thereof.


25. The use according to claim 23, wherein the caspase inhibitor is:




VX-166

or a pharmaceutically acceptable derivative thereof.


26. The use according to any one of claims 1-20, wherein the caspase inhibitor is selected from:



IDN8126



IDN9103




VX-765, belnacasan

,

or a pharmaceutically acceptable derivative thereof.

27. The use according to claim 26, wherein the caspase inhibitor is:




VX-765, belnacasan

,

or a pharmaceutically acceptable derivative thereof.

28. The use according to any one of claims 1- 26 wherein the caspase inhibitor is:



IDN9103

or a pharmaceutically acceptable derivative thereof.

29. The use of any one of claims 1-28, wherein the subject has been pre-treated with one or more other medications for liver disease.

30. The use of claim 29, wherein the one or more other medications are selected from among Furosemide, Spironolactone. Lactulose, Rifaximin, Propranolol, Nadolol, Carvedilol, Simtuzumab (GS-6624), Sorafenib, Serelaxin (RLX030), Timolol, NCX-1000, Terlipressin, NGM282 and LUM001, and analogs or derivatives thereof.

31. The use of any one of claims 1-30, wherein the subject has failed therapy for liver disease.

32. The use of any one of claims 1-30, wherein the subject has failed therapy for elevated MELD or its components.

33. The use of any one of claims 1-30, wherein the subject has failed therapy for liver cirrhosis.

34. Use of a therapeutically effective amount of a caspase inhibitor in the manufacture of a medicament for lowering or sustaining a MELD score or its components in a subject in need thereof, wherein the amount is effective to mitigate liver damage in the subject.

35. Use of a therapeutically effective amount of a caspase inhibitor in the manufacture of a medicament for lowering or sustaining a MELD score and its components in a subject in need thereof, wherein the amount is effective to lower elevated levels of INR, bilirubin or creatinine.

36. Use of a therapeutically effective amount of a caspase inhibitor in the manufacture of a medicament for lowering or sustaining a MELD score or its components in a subject in need thereof, wherein the amount is effective to lower elevated levels of liver enzyme in the subject.

37. The use of any one of claims 1-36, wherein the subject has failed therapy for elevated Child-Pugh or its components.

38. The use of any one of claims 1-36, wherein the subject has failed therapy for liver cirrhosis.

39. Use of a therapeutically effective amount of a caspase inhibitor in the manufacture of a medicament for lowering or sustaining a Child-Pugh score or its components in a subject in need thereof, wherein the amount is effective to mitigate liver damage in the subject.

40. Use of a therapeutically effective amount of a caspase inhibitor in the manufacture of a medicament for lowering or sustaining a Child-Pugh score or its

components in a subject in need thereof , wherein the amount is effective to lower elevated levels of Child-Pugh components.


41. Use of a therapeutically effective amount of a caspase inhibitor in the manufacture of a medicament for lowering or sustaining a Child-Pugh score or its components in a subject in need thereof, wherein the amount is effective to lower elevated levels of liver enzyme in the subject.

42. The use of claim 41, wherein the levels are of total liver enzyme, alanine aminotransferase or aspartate aminotransferase.


43. The use of claim 41 or claim 42, wherein the elevated level of liver enzyme is lowered by about 100% to about 1%.

44. The use of claim 43, wherein the elevated level of liver enzyme is lowered by at least 99%, at least 90%, at least 80%, at least 70%, at least 60%, at least 50%, at least 40%, at least 30%, at least 20%, at least 10%, at least 5%, at least 2% or at least 1%.


45. The use of any one of claims 29-44, wherein the caspase inhibitor is selected from:




IDN6556, emricasan




IDN7314




IDN6734




CTS5814




IDN7568




CTS2891




IDN8126



IDN9103




VX-166




VX-765, belnacasan

or a pharmaceutically acceptable derivative thereof.


46. The use according to any one of claims 29-44, wherein the caspase inhibitor is selected from:




IDN6556, emricasan




IDN7314




IDN6734



CTS5814




IDN7568




CTS2891

or a pharmaceutically acceptable derivative thereof.

47. A method according to any one of claims 30-45, wherein the caspase inhibitor is selected from:




IDN6556, emricasan



VX-166


or a pharmaceutically acceptable derivative thereof.

48. The use of claim 47, wherein the caspase inhibitor is:



IDN6556, emricasan

49. The according to claim 47, wherein the caspase inhibitor is:




VX-166


,

or a pharmaceutically acceptable derivative thereof.


50. The use according to any one of claims 29-44, wherein the caspase inhibitor is selected from:



IDN8126



IDN9103



VX-765, belnacasan

or a pharmaceutically acceptable derivative thereof.

51. A pharmaceutical composition, comprising a caspase inhibitor and a pharmaceutically acceptable excipient, wherein the caspase inhibitor is in an amount that is therapeutically effective in the treatment of an elevated MELD score or its components.

52. A pharmaceutical composition, comprising a caspase inhibitor and a pharmaceutically acceptable excipient, wherein the caspase inhibitor is in an amount that is therapeutically effective in the treatment of an elevated Child-Pugh score or its components.

53. The composition of claim 51 or 52 that is formulated for oral administration.


54. The composition of claim 51 or 52that is formulated for nasogastric administration.

55. The composition of claim 51 or 52, wherein the caspase inhibitor is in amount of about 1 mg to about 100 mg.


56. The composition of claim 51 or 52, wherein the caspase inhibitor is in an amount of about 25 mg to about 50 mg.

57. The composition of any one of claims 1-56, wherein the caspase inhibitor is administered at least once daily.


58. The composition according to any one of claims 51-57, wherein the caspase inhibitor is selected from:




IDN6556, emricasan




IDN7314




IDN6734




CTS5814




IDN7568




CTS2891




IDN8126



IDN9103




VX-166




VX-765, belnacasan

or a pharmaceutically acceptable derivative thereof.


59. The composition according to any of claim 51-57, wherein the caspase inhibitor is selected from:




IDN6556, emricasan




IDN7314




IDN6734



CTS5814




IDN7568




CTS2891

or a pharmaceutically acceptable derivative thereof.

60. The composition according to any of claim 51-57, wherein the caspase inhibitor is selected from:




IDN6556, emricasan



VX-166

or a pharmaceutically acceptable derivative thereof.

61. The composition according to claim 60, wherein the caspase inhibitor is selected from:



IDN6556, emricasan

or a pharmaceutically acceptable derivative thereof.

62. A kit, comprising a caspase inhibitor and a second pharmacologically active substance, wherein the second pharmacologically active substance is for treating a subject with an elevated MELD score or its components.

63. A kit, comprising a caspase inhibitor and a second pharmacologically active substance, wherein the second pharmacologically active substance is for treating a subject with an elevated Child-Pugh score or its components.


64. The kit of claim 62 or 63, wherein the caspase inhibitor is in a composition comprising the caspase inhibitor and a pharmaceutically acceptable excipient.

65. The kit of claim 62or 63, wherein the second pharmacologically active substance is in a composition comprising the caspase inhibitor and a pharmaceutically acceptable excipient.


66. The kit of any one of claims 62-65, wherein the caspase inhibitor and the second pharmacologically active substance are in a single composition.

67. The kit of any one of claims 62-65, wherein the caspase inhibitor and the second pharmacologically active substance are in two different compositions.


68. The kit of any one of claims 62-67, wherein the caspase inhibitor is selected from:




IDN6556, emricasan




IDN7314




IDN6734




CTS5814




IDN7568




CTS2891




IDN8126



IDN9103




VX-166




VX-765, belnacasan

or a pharmaceutically acceptable derivative thereof.


69. A kit according to any one of claims 62-67, wherein the caspase inhibitor is selected from:




IDN6556, emricasan




IDN7314




IDN6734



CTS5814




IDN7568




CTS2891

or a pharmaceutically acceptable derivative thereof.

70. A kit according to any one of claims 62-67, wherein the caspase inhibitor is selected from:




IDN6556, emricasan



VX-166

or a pharmaceutically acceptable derivative thereof.

71. The kit according to claim 70, wherein the caspase inhibitor is:



IDN6556, emricasan

or a pharmaceutically acceptable derivative thereof.

72. A kit according to any one of claims 62-71, wherein the second pharmacologically active substance is selected from: Furosemide, Spironolactone. Lactulose, Rifaximin, Propranolol, Nadolol, Carvedilol, Simtuzumab (GS-6624), Sorafenib, Serelaxin (RLX030), Timolol, NCX-1000, Terlipressin, NGM282 and LUM001, and analogs or derivatives thereof.

73. A kit according to any one of claims 62-71, wherein the second pharmacologically active substance is a compound for the treatment of an elevated MELD score.

74. A kit according to any one of claims 62-71, wherein the second pharmacologically active substance is a compound for the treatment of an elevated Child-Pugh score.

75. The kit of any one of claims 62-71, wherein the second pharmacologically active substance is a compound for the treatment of cirrhosis.

76. The use of any one of claims 1-50, further comprising a second pharmacologically active substance that is to be administered to the subject, wherein the second pharmacologically active substance is a compound for use in the treatment of liver disease.

77. The use of claim 76, wherein the second pharmacologically active substance is a compound for use in the treatment of cirrhosis.

78. The use of claim 76 or claim 77, wherein the second pharmacologically active substance is to be administered simultaneously with the caspase inhibitor.

79. The use of claim 76 or claim 77, wherein the second pharmacologically active substance is to be administered sequentially in any order relative to the caspase inhibitor.

80. The use of any one of claims 77-79, wherein the second pharmacologically active substance is for use in the treatment of cirrhosis.

81. The use of any one of claims 77-80, wherein the second pharmacologically active substance is selected from: Furosemide, Spironolactone. Lactulose, Rifaximin, Simtuzumab (GS-6624), Sorafenib, Serelaxin (RLX030), Timolol, NCX-1000, Terlipressin, NGM282 and LUM001, and analogs or derivatives thereof.

82. The use of any one of claims 77-80, wherein the second pharmacologically active substance is for use in the treatment of portal hypertension or elevated MELD score.

83. The use of claim 83, wherein the second pharmacologically active substance is selected from Propranolol, Nadolol, Carvedilol and Timolol.

84. The use of any one of claims 1- 50 and 76-83, wherein the subject has failed therapy for elevated MELD score.

85. The use of any one of claims 1-50 and 76-83, wherein the subject has failed therapy for liver cirrhosis.

86. Use of a therapeutically effective amount of a caspase inhibitor in the manufacture of a medicament for treating liver disease in a subject, wherein the subject has an elevated MELD score and the amount being effective to mitigate liver disease and/or lower or sustain the MELD score.

87. The use of claim 86, wherein the MELD score is greater than 10.

88. The use of claim 86, wherein the MELD score is greater than 14.

89. The use of any one of claims 86-88, wherein the administration of the caspase inhibitor lowers the one or more components of the MELD score.

90. The use of any one of claims 86-89, wherein the administration of the caspase inhibitor lowers the MELD score by 10% or more.

91. The use of any one of claims 86-90, wherein the administration of the caspase inhibitor lowers the MELD score by at least 1 point.

92. Use of a therapeutically effective amount of a caspase inhibitor in the manufacture of a medicament for treating liver cirrhosis and preventing an elevated MELD score in a subject, wherein administration of the caspase inhibitor mitigates liver cirrhosis and/or reduces the risk of occurrence of elevated MELD score.

93. The use of claim92, wherein the subject has an elevated level of INR, creatinine and/or bilirubin and wherein administration of the caspase inhibitor lowers the level of INR, creatinine and/or bilirubin in the subject.

94. The use of any one of claims 1-50 and, 76-93 wherein the subject has failed therapy for elevated Child-Pugh score.

95. The use of any one of claims 1- 50 and 76-93, wherein the subject has failed therapy for liver cirrhosis.

96. Use of a therapeutically effective amount of a caspase inhibitor in the manufacture of a medicament for treating liver disease in a subject, wherein the subject has an elevated Child-Pugh score, and the amount being effective to mitigate liver disease and/or lower or sustain said Child-Pugh score.

97. The use of claim 96, wherein the Child-Pugh score is greater than Class A.

98. The use of claim 96, wherein the Child-Pugh score is greater than Class B.

99. The use of any one of claims 96-98, wherein the administration of the caspase inhibitor lowers the one or more components of the Child-Pugh score.

100. The use of any one of claims 96-99, wherein the administration of the caspase inhibitor lowers the Child-Pugh score by 10% or more.

101. The use of any one of claims 96-100, wherein the administration of the caspase inhibitor lowers the Child-Pugh score by at least 1 point.

102. Use of a therapeutically effective amount of a caspase inhibitor in the manufacture of a medicament for treating liver cirrhosis and preventing an elevated Child-Pugh score in a subject, wherein administration of the caspase inhibitor mitigates the liver cirrhosis and/or reduces the risk of occurrence of elevated Child-Pugh score .